Summary
Other Scenarios:
- PFE - JNJ
- PFE - NVS
- JNJ - RHHBY
- NVS - RHHBY
| Buyer: | Pfizer Inc (PFE) | Last Price: | 22.57 | Market Cap.: | 176.09B |
|---|---|---|---|---|---|
| Target: | Roche Holding AG (RHHBY) | Last Price: | 40.32 | Market Cap.: | 139.11B |
Lines of Business Summary:
- Pfizer Inc (PFE) competes in 2 industries and 403 product/service groups
- Roche Holding AG (RHHBY) competes in 2 industries and 227 product/service groups
- A combined entity will have 7% Product/Service Group overlap
- Pfizer Inc (PFE) has 12 and Roche Holding AG (RHHBY) has 9 suppliers that rely on a material % of their business. They share 2 in common.
- Pfizer Inc (PFE) has 3 and Roche Holding AG (RHHBY) has 0 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Consumer |
|
890 | |
Consumer Products and Services |
|
341 | |
|
Healthcare |
|
|
732 |
|
Biopharmaceuticals |
|
|
334 |
|
Healthcare Services |
|
122 | |
|
Medical Devices |
|
|
177 |
|
Nutritional Health |
|
26 | |
|
Outsourced Biomedical Services |
|
|
39 |
|
Scientific Products |
|
23 | |
|
Veterinary Products and Services |
|
8 | |
|
Technology |
|
806 | |
|
Information Technology (IT) Services |
|
105 | |
|
Software |
|
246 |
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 446)
|
Target (Total: 301)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 70)
|
Target (Total: 64)
|
Buyer (Total: 26)
|
Target (Total: 27)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 110,600 | 80,653 |
| Revenue Per Employee | 615,937.1 | 664,913.5 |
| Total Revenue | 15,405.0 | 20,860.0 |
| Total Expenses | 12,852.0 | 14,866.0 |
Other Revenue
|
n/a | n/a |
|
Cost of Revenue
|
2,895.0 | 5,844.0 |
|
SG&A Expense
|
4,108.0 | 5,090.0 |
|
Research & Development
|
1,765.0 | 4,200.0 |
|
Other Operating Expense
|
109.0 | -786.0 |
|
Operating Income
|
2,553.0 | 5,994.0 |
|
Unusual Income
|
2,246.0 | 507.0 |
|
LT Debt to Capital
|
28.72 | 65.98 |
|
Fwd P/E
|
10.21 | 10.09 |
|
Fwd P/Rev
|
2.93 | 2.93 |
| Book Value | 83,213.0 | 12,095.0 |
|
Curr Portion of LTD/Cap Lease
|
n/a | 3,394.0 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company operates in two segments: Biopharmaceutical and Diversified. Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which includes products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Diversified includes Animal Health products; Consumer Healthcare products , such as pain management therapies, cough/cold/allergy remedies, dietary supplements, hemorrhoidal care and other personal care items; Nutrition products such as infant and toddler formula products, and Capsugel. On January 31, 2011, it acquired approximately 92.5% of King?s common stock. In August 2011, it sold its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P.
Target
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It belongs to the Roche Group that operates through subsidiaries and associated companies around the world. It discovers, develops and provides diagnostic and therapeutic products and services from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. Roche has two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals are divided into three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. It operates in the United States, Western Europe, Japan, CEMAI (Central and Eastern Europe, Middle East, Africa, Central Asia, Indian Subcontinent), Latin America, Asia-Pacific and Other regions. Diagnostics include five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. It is structured into five segments: North America; Asia-Pacific; EMEA (Europe, Middle East and Africa); Latin America and Japan.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
78.17 | 80.52 |
|
Operating Margin %
|
19.03 | 52.74 |
|
Quick Ratio
|
1.41 | 1.3 |
|
Current Ratio
|
2.02 | 1.74 |
|
Coverage Ratio
|
n/a | n/a |
| Total Assets | 185,683.0 | 61,576.0 |
| Return on Equity % | 63.08 | 354.76 |
| Return on Assets % | 28.28 | 69.68 |
|
Cash+ ST Inv. Per Share
|
3.16 | 13.29 |
| Total Debt | 39,069.0 | 26,853.0 |
| Total Debt to Equity % | 46.93 | 222.02 |
| Total Debt to Tangible Equity % | n/a | n/a |
|
Debt to Asset %
|
21.04 | 43.61 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
Consumer Products and Services |
|
|
|
Personal Care and Cleaning Products
Companies engaged in the manufacturing of personal care products, such as cosmetics, fragrances, skin lotion, sanitary/personal care paper (tissues), shampoo and other toiletries; and household cleaning products, such as window/surface cleaner, and table polish.
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes therapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Healthcare Services |
|
|
|
Patient Care
The Patient Care Subsector is comprised of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
|
|
|
|
Medical Devices |
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
|
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
|
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
Buyer Products:
|
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
|
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Bioanalytical Services
The Bioanalytical Services Subsector includes outsourced services that utilize bioanalytical instruments to analyze biological samples.
|
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of chemical and biochemical samples.
|
|
|
|
Bioanalytical Instruments
The Bioanalytical Subsector includes scientific products, devices, apparatuses, and consumables used to determine the quantitative and qualitative nature of a biological samples.
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Diagnostics
The Veterinary Diagnostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.
Buyer Products:
|
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Technology |
|
|
|
Information Technology (IT) Services |
|
|
|
Enterprise and Technology Consulting
Information technology related to consulting services designed to improve a client company's operating efficiency, and business capabilities through the expert application of information technology resources and best practices. These services can be delivered on a project-by-project basis, or via an on-going relationship.
|
|
|
|
Software |
|
|
|
Industry-Specific
Software that has functionality specific to a vertical industry.
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Consumer |
|
|
|
Consumer Products and Services |
|
|
Personal Care and Cleaning Products |
|
|
|
Skin Care
Companies engaged in the manufacturing of skin care products, such as suntan lotion, skin lotion, sanitizer, shaving cream, and moisturizer. Also includes manufacturers of non-electrical shaving equipment.
Buyer Products:
|
|
|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that treat allergic shock by stimulating alpha and beta adrenergic receptors.
Buyer Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the risk of chest pains by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Agonists
Therapeutics that treat abnormal rhythm of the heart by increasing the entry of sodium ions into the heart muscle to extending the time an electrical impulse travels across a neuron.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that assist the primary treatment of the ineffective pumping of the heart by dilating blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Selective Aldosterone Receptor Antagonists (SARA)
Therapeutics that selectively block the action of aldosterone, a chemical implicated in causing cardiovascular disease.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the ineffective pumping of the heart by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Adjunctive Treatment |
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Anticoagulating Agents |
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat irreversible damage to the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that treat the ineffective pumping of the heart by dissolving blood clots in blood vessels.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Buyer Products:
|
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting stimulation of alpha adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Selective Aldosterone Receptor Antagonists (SARA)
Therapeutics that selectively block the action of aldosterone, a chemical implicated in causing hypertension.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Buyer Products:
|
|
|
|
Primary Pulmonary Hypertension |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that treat hypertension by increasing level of nitric oxide that help to dilate blood vessels.
Buyer Products:
|
|
|
|
Stroke |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that prevent strokes by blocking the influx of calcium ions into vascular cells.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat damage to nerve cells of the brain by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that prevent or treat damage to nerve cells of the brain by dissolving blood clots in blood vessels.
Target Products:
|
|
|
|
Thromboembolism |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Factor Xa Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.
Buyer Products:
|
|
|
|
Thrombolytic Agents
Therapeutics that treat obstructions of blood vessels by dissolving blood clots.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Chronic Urticaria |
|
|
|
Monoclonal Antibodies
Therapeutics that treat chronic urticaria by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site, as well as prevent the growth of bacteria.
Buyer Products:
|
|
|
|
Pruritus |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Janus-Associated Kinase (JAK) Inhibitors
Therapeutics that treat psoriasis by selectively inhibiting the production of a variety of inflammatory causing cytokines.
Buyer Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Gastric |
|
|
|
Antisecretory Agents
Therapeutics that treat peptic ulcers by preventing the secretion of acid.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroparesis |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat gastroparesis by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Buyer Products:
|
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Familial Adenomatous Polyposis (FAP) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat colon polyps by inducing suicide in the abnormal cells.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Intestinal Intubation |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that cause bowel evacuation prior to intubation by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Rectal Disorders |
|
|
|
Hemorrhoids |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat hemorrhoids by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat or suppress inflammation by preventing the accumulation of inflammatory cells like leucocytes and macrophages to the inflammation sites.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that prevent edema by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hepatitis |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Adrenal Gland Disorders |
|
|
|
Primary Aldosteronism |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat aldosteronism by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Diabetic Neuropathy |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat diabetic neuropathy by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Alpha-Glucosidase Inhibitors
Therapeutics that treat diabetes by stopping the enzyme that releases glucose from larger molecules.
Buyer Products:
|
|
|
|
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)
Therapeutics that treat non-insulin dependent diabetes by stimulating the Glucagon-Like Peptide (GLP) receptor. GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Cortisols
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Buyer Products:
|
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat gouty arthritis by preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Buyer Products:
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that treat hypercholesterolemia by reducing the levels of very low-density lipoprotein and increasing levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Lysosomal Storage Diseases |
|
|
|
Gaucher Disease |
|
|
|
Enzyme Replacement Therapy
Therapeutics that treat Gaucher's Disease by providing the missing enzymes that contributes to the disease symptoms.
Buyer Products:
|
|
|
|
Parathyroid Gland Disorders |
|
|
|
Hyperparathyroidism (HPT) |
|
|
|
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Growth Hormone Receptor Antagonists
Therapeutics that treat acromegaly by binding to and thus blocking growth hormone receptors. This results in decreased secretion of growth hormone as well as IGF-1, which is responsible for the debilitating effects of the disease.
Buyer Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Buyer Products:
|
|
|
|
Pituitary Hyperthyroidism (TSH-Induced) |
|
|
|
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.
Buyer Products:
|
|
|
|
Severe Short Stature |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
Target Products:
|
|
|
|
Turner`s Syndrome |
|
|
|
Growth Hormones
Therapeutics similar to pituitary hormones, which stimulate body growth and development.
Buyer Products:
Target Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Female |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Estrogens/Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat menopause by a combination of natural female hormone and synthetic female hormone analogues.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat vasomotor symptoms associated with menopause by selectively preventing the removal of norepinephrine.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Thyroid Gland Disorders |
|
|
|
Hyperthyroidism |
|
|
|
Thyroid Hormone Synthesis Inhibitors
Therapeutics that stop the production of thyroid hormones.
Buyer Products:
|
|
|
|
Hypothyroidism |
|
|
|
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Hemophilia |
|
|
|
Hemophilia A |
|
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Buyer Products:
|
|
|
|
Hemophilia B |
|
|
|
Clotting Agents
Therapeutics that assist in blood coagulation.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
Bile Acid Binding Agents
Therapeutics that treat hypercholesterolemia by binding bile acids in the intestine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat high blood pressure and high cholesterol by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine, and by blocking cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Cholesteryl Ester Transfer Protein Inhibitors (CETP)
Therapeutics that treat high cholesterol by interrupting with the transfer of lipids between lipoproteins.
Buyer Products:
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increasing
levels of high-density lipoproteins.
Buyer Products:
|
|
|
|
Hypocalcemia |
|
|
|
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.
Target Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocytopenia |
|
|
|
Platelet Growth Factors
Therapeutics that promote the growth of particular blood coagulating factors.
Buyer Products:
|
|
|
|
White Blood Cell (WBC) Disorders |
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of white blood cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) Associated Vasculitis |
|
|
|
Monoclonal Antibodies
Therapeutics that treat Wegener's Granulomatosis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Arthritis |
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints coupled with red, scaly skin patches by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat pain associated with chronic inflammation of the joints, without upsetting the stomach with a non-steroidal compound and an anti-ulcer agent.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Janus-Associated Kinase (JAK) Inhibitors
Therapeutics that treat rheumatoid arthritis by selectively inhibiting the production of a variety of inflammatory causing cytokines.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat systemic lupus by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Psoriasis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat psoriasis by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Target Products:
|
|
|
|
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Aminoglycosides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
Target Products:
|
|
|
|
Glycylcyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes. This class of antibiotics is a group of tetracycline analogues developed to target tetracycline-resistant strains of bacteria.
Buyer Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Oxazolidinones
Therapeutics that treat a wide variety of infections by inhibiting early initiation of bacterial protein synthesis.
Buyer Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Penicillin Derivatives/Beta-Lactamase Inhibitors
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication and increasing susceptibility to penicillin derived compounds.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotics)
Therapeutics that treat bacterial infections of the skin with a steroidal compound and a compound that kills or inhibits the growth of bacteria.
Buyer Products:
|
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Penicillin Derivatives
Therapeutics that treat dermal infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Shigellosis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat an infection of the intestines caused by Shigella by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Ocular Infections |
|
|
|
Aminoglycosides/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis and damaging the cell membrane.
Buyer Products:
|
|
|
|
Aminoglycosides/Polypeptides/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting bacterial protein synthesis, damaging the cell membrane, and suppressing the full immune response.
Buyer Products:
|
|
|
|
Tetracyclines/Polypeptides
Therapeutics that treat bacterial infections of the eye by inhibiting protein synthesis and damaging the cell membrane.
Buyer Products:
|
|
|
|
Tetracyclines/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat bacterial infections of the eye by inhibiting protein synthesis, damaging the cell membrane and suppressing the full immune response.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
External Ear Canal Infections |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)/Antibacterial Agents (Antibiotic)
Therapeutics that treat bacterial infections of the external auditory canal with a steroidal compound and by killing or inhibiting the growth of microorganisms.
Buyer Products:
|
|
|
|
Otitis Media |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
Target Products:
|
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Bronchitis |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
Target Products:
|
|
|
|
Pneumonia |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Buyer Products:
|
|
|
|
Polypeptides
Therapeutics that treat bacterial infections by inhibiting bacterial cell wall synthesis.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Tuberculosis |
|
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Systemic |
|
|
|
Mycobacterium Avium Complex (MAC) Disease |
|
|
|
Antitubercular Agents
Therapeutics that treat infection caused Mycobacterium avium in soil that spreads to a variety of organs and tissues by inhibiting bacterial and mycobacterial RNA synthesis.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Gonorrhea |
|
|
|
Penicillin Derivatives
Therapeutics that treat a common sexually transmitted disease caused by gonococcus bacterium by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Aminoglycosides
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Buyer Products:
Target Products:
|
|
|
|
Penicillin Derivatives
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by inhibiting bacterial cell wall synthesis during active multiplication.
Buyer Products:
|
|
|
|
Vaginitis |
|
|
|
Lincosamides
Therapeutics that treat inflammation of the mucous membrane of the vagina caused by bacterial infection by inhibiting bacterial protein synthesis.
Buyer Products:
|
|
|
|
Vaccines |
|
|
|
Bacterial |
|
|
|
Combination |
|
|
|
Diphtheria/Tetanus (DT)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria and tetanus.
Buyer Products:
|
|
|
|
Single Target |
|
|
|
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.
Buyer Products:
|
|
|
|
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.
Buyer Products:
|
|
|
|
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.
Buyer Products:
|
|
|
|
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
Target Products:
|
|
|
|
Echinocandins
Therapeutics that treat fungal infections by inhibiting the synthesis of a major cell wall component.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Digestive System |
|
|
|
Mucous |
|
|
|
Candidiasis |
|
|
|
Echinocandins
Therapeutics that treat fungal infections due to candidiasis through a broad spectrum fungicidal action.
Buyer Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pharynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumocystis Carinii Pneumonia (PCP) |
|
|
|
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by interfering with folic acid synthesis and growth of organism.
Target Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Aminoquinolines/Macrolides
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth and inhibiting RNA-dependent protein synthesis.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Hepadnavirus |
|
|
|
Hepatitis B |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.
Target Products:
|
|
|
|
Herpesvirus |
|
|
|
Cytomegalovirus (CMV) |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA blocking the action of an essential enzyme.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by blocking the action of an essential enzyme.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Flavivirus |
|
|
|
Hepatitis C |
|
|
|
Chronic |
|
|
|
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.
Target Products:
|
|
|
|
Orthomyxovirus |
|
|
|
Influenza A |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.
Target Products:
|
|
|
|
Influenza B |
|
|
|
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.
Target Products:
|
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
CCR-5 Inhibitors
Therapeutics that help manage HIV by blocking the virus from entering human cells.
Buyer Products:
|
|
|
|
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.
Target Products:
|
|
|
|
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.
Buyer Products:
|
|
|
|
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.
Buyer Products:
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Bone Fractures |
|
|
|
Growth Factor |
|
|
|
Recombinant Human Bone Morphogenetic Protein (rhBMP)
Therapeutics that induce the formation of bone and cartilage.
Buyer Products:
|
|
|
|
Osteoporosis |
|
|
|
Estrogens/Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by providing female hormones and other endocrine modulating substances which decrease the rate of bone loss.
Buyer Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Target Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.
Buyer Products:
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Immunotherapy |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ankylosing spondylitis interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat ankylosing spondylitis by selectively blocking cyclooxygenase 2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat ankylosing spondylitis by blocking the effect of TNF-alpha, a pro-inflammatory molecule.
Buyer Products:
|
|
|
|
Dupuytren`s Disease |
|
|
|
Debriding Agents
Therapeutics that treat Depuytren's Disease by removing the fibrous material from in/around the palm of the hand.
Buyer Products:
|
|
|
|
Fibromyalgia Syndrome (FMS) |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Fibromyalgia Syndrome by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Fibromyalgia Syndrome by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat inflammation by inhibiting the action of prostaglandins while simultaneously protecting the stomach from the pain killing medication.
Buyer Products:
|
|
|
|
Psoriatic Arthritis |
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/GI Protective Agents
Therapeutics that treat pain associated with chronic inflammation of the joints, without upsetting the stomach with a non-steroidal compound and an anti-ulcer agent.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Janus-Associated Kinase (JAK) Inhibitors
Therapeutics that treat rheumatoid arthritis by selectively inhibiting the production of a variety of inflammatory causing cytokines.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)
Therapeutics that treat chronic inflammation of the joints by blocking the action of tumor necrosis factor.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Buyer Products:
|
|
|
|
Mitochondrial Pore Blockers
Therapeutics that treat Alzheimer's Disease by blocking molecules transport across mitochondrial pores, which may lead to the prevention of brain cell death.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat Alzheimer's Disease by interfering with specific immune pathways implicated in the progression of the disease.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat Petit Mal Seizures by preventing the entrance of calcium into nerve cells.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat status epilepticus by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
|
Huntington`s Disease (Huntington`s Chorea) |
|
|
|
Mitochondrial Pore Blockers
Therapeutics that treat Huntington's Disease by blocking molecules transport across mitochondrial pores, which may lead to the prevention of brain cell death.
Buyer Products:
|
|
|
|
Motion Sickness |
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat multiple sclerosis by interfering with specific immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Neuropathy |
|
|
|
Transthyretin (TTR) Amyloidosis |
|
|
|
Transthyretin (TTR) Stabilizers
Therapeutics that treat Transthyretin Amyloidosis, a hereditary form of neuropathy, also known as Familial amyloid polyneuropathy (FAP), by stabilizing the transthyretin protein.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
Target Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat panic disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Serotonin/Dopamine Receptor Blocking Agents
Therapeutics that treat bipolar disorders by blocking serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Estrogens/Progestins
Therapeutics that treat premenstrual dysphoric disorders by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Glycine Reuptake Inhibitors
Therapeutics that treat schizophrenia by inhibiting the reuptake of glycine by neurotransmitters.
Target Products:
|
|
|
|
Serotonin/Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Serotonin/Dopamine Receptor Partial Agonists
Therapeutics that treat schizophrenia by enhancing activity in both serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Antihistamines/Analgesics/Antipyretics
Therapeutics that treat insomnia by preventing the functions of histamine on tissues as well as treating pain and suppressing fever.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Hemorrhage |
|
|
|
Prostaglandins
Therapeutics that treat hemorrhage by acting as vasoconstrictors, thus reducing blood flow.
Buyer Products:
|
|
|
|
Induction/Cervical Ripening |
|
|
|
Oxytocic Agents
Therapeutics that induce contractions by increasing the levels of intracellular calcium in the uterine smooth muscle thus mimicking uterine contractions and transiently impeding uterine blood flow.
Buyer Products:
|
|
|
|
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.
Buyer Products:
|
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Buyer Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Buyer Products:
|
|
|
|
Termination (Abortion) |
|
|
|
Prostaglandins
Therapeutics that induce contractions by acting directly on the myometrium thus stimulating myometrial contractions in the uterus.
Buyer Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Endometriosis |
|
|
|
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.
Buyer Products:
|
|
|
|
Progestins
Therapeutics that treat endometriosis pain by increasing progesterone level in the body.
Buyer Products:
|
|
|
|
Ovarian |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
These therapeutics are male sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Buyer Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.
Buyer Products:
|
|
|
|
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat disorders characterized by thinning of the vaginal walls blocking estrogen receptors.
Buyer Products:
|
|
|
|
Dryness |
|
|
|
Estrogens
These are female sex hormones.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat breast cancer by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat localized breast cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Aromatase Inhibitors
Therapeutics that treat and manage breast cancer by interfering with estrogen production in peripheral tissues.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Cardioprotective Agents
Therapeutics that help reduce damage to the heart caused by treatments for breast cancer by interfering with free radical generation which results in cardiomyopathy.
Buyer Products:
|
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Basal Cell Carcinoma |
|
|
|
Hedgehog Pathway Inhibitors
Therapeutics that treat and manage cancers arising from the epidermal basal cells by inhibiting signaling in the Hedgehog pathway, which functions to regulate cell growth.
Target Products:
|
|
|
|
Kaposi`s Sarcoma |
|
|
|
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Malignant Melanoma |
|
|
|
Raf Kinase Inhibitors
Therapeutics that treat skin cancer by interrupting the signaling pathways that are responsible for tumor cell proliferation.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Antimetabolite Agents |
|
|
|
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal tumors that have spread beyond their original tumor site by inhibiting the production of DNA.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Gastric Cancer (Stomach Cancer) |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the stomach by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat gastric cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat gastric cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Hepatic Cancer (Liver Cancer) |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage hepatic (liver) cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Target Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Localized |
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat localized pancreatic cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Target Products:
|
|
|
|
Endocrinology |
|
|
|
Thyroid Gland |
|
|
|
Localized |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the thyroid gland by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Hairy Cell |
|
|
|
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.
Target Products:
|
|
|
|
Lymphocytic (CLL) |
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.
Target Products:
|
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Chronic |
|
|
|
Myelogenous (CML) |
|
|
|
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.
Target Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat myelogenous cancers by inhibiting the action of tyrosine kinase, compounds that play a vital role in cell division.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.
Buyer Products:
Target Products:
|
|
|
|
Neurology |
|
|
|
Brain Cancer |
|
|
|
Glioma |
|
|
|
Glioblastoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage tumors of the glial cells by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Neuroblastoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a and manage cancer of primitive ganglion cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
EGFR-TK Inhibitors/Monoclonal Antibodies
Therapeutics that treat lung cancer by blocking the tyrosine kinase enzyme and by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.
Target Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
Target Products:
|
|
|
|
Toll-Like Receptor Agonists
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by stimulating the immune system.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by inhibit a specific enzyme needed for the replication and transcription of DNA.
Buyer Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat lung cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Kidney Cancer (Renal Cell Carcinoma) |
|
|
|
Metastatic |
|
|
|
Mammalian Target Of Rapamycin (mTOR) Inhibitors
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by inhibiting signals required for cell cycle progression, cell growth, and proliferation.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Tyrosine Kinase Inhibitors
Therapeutics that treat kidney cancer by inhibiting the action of tyrosine kinase, enzymes that play a vital role in cell division.
Buyer Products:
|
|
|
|
Wilm`s Tumor (Nephroblastoma) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage tumors of the kidney by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Monoclonal Antibodies
Therapeutics that treat ovarian cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Monoclonal Antibodies
Therapeutics that treat and manage ovarian cancers that have spread beyond their original tumor site by binding to specific structures on the surface of the tumor, eliciting a reaction which results in tumor cell death.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Localized |
|
|
|
Estrogens
Therapeutics that treat and manage primary tumors of the prostate gland by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Buyer Products:
|
|
|
|
Gonadotropin Releasing Hormone (GnRH) Antagonists
Therapeutics that treat and manage primary tumors of the prostate gland by blocking the action of gonadotropin releasing hormone and thus decreasing levels of testosterone.
Buyer Products:
|
|
|
|
Urinary Bladder Cancer |
|
|
|
Transitional Cell Carcinoma |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers arising from the lining of the bladder by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Edema |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular edema by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Target Products:
|
|
|
|
Glaucoma |
|
|
|
Prostanoid Selective FP Receptor Agonists
Therapeutics that increase the outflow of fluid of the eye.
Buyer Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Antibacterial Agents (Antibiotics)
Therapeutics that treat infections by inhibiting bacterial replication.
Buyer Products:
|
|
|
|
Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat infections by inhibiting bacterial replication as well as prevent cells that cause inflammation from adhering to the inflammation site.
Buyer Products:
|
|
|
|
Tetracyclines/Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat irritation and inflammation of the eye by inhibiting the growth of bacteria and by preventing the accumulation of inflammatory cells.
Buyer Products:
|
|
|
|
Macular Degeneration (AMD) |
|
|
|
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.
Buyer Products:
Target Products:
|
|
|
|
Retinitis |
|
|
|
AIDS-Related Cytomegalovirus (CMV) Retinitis |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Ocular Hypertension |
|
|
|
Prostanoid Selective FP Receptor Agonists
Therapeutics that treat a condition characterized by increased pressure in the fluid of the eye by increasing the outflow of fluid of the eye.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that result in anesthesia by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Primary |
|
|
|
Barbiturates
Therapeutics that result in anesthesia due to a general sedative effect by enhancing the response to gamma aminobutyric acid and decrease excitability by directly suppressing conduction in the brain.
Buyer Products:
|
|
|
|
Reversal |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Target Products:
|
|
|
|
Narcotics |
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioids/Opioid Antagonists
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain, and at the same time reduce the likelihood of physical dependence or addiction.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat pain by inhibiting the reuptake of GABA, which increases the levels of GABA in the synapses.
Buyer Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially, as well as prevent inflammation by inhibiting the action of prostaglandins.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Complications |
|
|
|
Bacterial Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Prophylactic Treatments |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Cystic Fibrosis (CF) |
|
|
|
Recombinant Human Deoxyribonuclease I
Therapeutics that relieve symptoms of cystic fibrosis by hydrolyzing the DNA in the sputum of cystic fibrosis patients thus reducing viscosity of the secretions and aiding lung function.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Anticholinergic Agents/Opioids
Therapeutics that treat coughs and colds by relieving pain and fever as well as suppressing cough.
Buyer Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, relieving or preventing coughs, relieving pain, and reducing fever.
Buyer Products:
|
|
|
|
Antitussives
Therapeutics that relieve or prevent coughs.
Buyer Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Buyer Products:
|
|
|
|
Decongestants/Analgesics
Therapeutics that treat coughs and colds by reducing mucous build up and relieving pain.
Buyer Products:
|
|
|
|
Decongestants/Antitussives
Therapeutics that treat coughs and colds by reducing mucous build up and suppressing the cough.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and helping in the ejection of the mucous.
Buyer Products:
|
|
|
|
Decongestants/Antitussives/Expectorants/Analgesics/Antipyretics
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing the cough, helping in the ejection of mucous and helping relieve fever and pain.
Buyer Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
Cardiovascular System |
|
|
|
Complications |
|
|
|
Peripheral Arterial Occlusion |
|
|
|
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Post-Operative Ileus/Constipation |
|
|
|
Opioid Receptor Antagonists
Therapeutics that treat constipation by blocking the mu opioid receptors in the intestines.
Buyer Products:
|
|
|
|
General |
|
|
|
Complications |
|
|
|
Hemorrhage |
|
|
|
Coagulating Agents (Coagulants)
Therapeutics that treat bleeding during a surgical procedure by promoting blood clotting.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Deep Vein Thrombosis (DVT) |
|
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
|
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.
Buyer Products:
|
|
|
|
Factor Xa Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by preventing thrombin generation, which is responsible for blood clotting.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of surgical complications in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Animal Poisoning |
|
|
|
Snakes |
|
|
|
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.
Buyer Products:
|
|
|
|
Chemical Poisoning |
|
|
|
Anticholinergic Agents |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that are meant to treat toxic overdose of drugs with anticholinergic properties by inhibiting the action of acetylcholinesterase.
Buyer Products:
|
|
|
|
Cyanide |
|
|
|
Chelating Agents
Therapeutics that form chemical complexes with cyanide and are subsequently excreted.
Buyer Products:
|
|
|
|
Nerve Gas |
|
|
|
Anticholinergic Agents
Therapeutics that treat toxicity due to nerve agent/gas by antagonizing the muscarine-like actions of acetylcholine and other choline esters.
Buyer Products:
|
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Bone Marrow |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Neutropenia |
|
|
|
Colony Stimulating Factors (CSF) |
|
|
|
Granulocyte (rhG-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cells called granulocytes.
Target Products:
|
|
|
|
Heart |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.
Target Products:
|
|
|
|
Hepatic (Liver) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
Target Products:
|
|
|
|
Lung |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Pancreas |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Complications |
|
|
|
Cytomegalovirus (CMV) Infections |
|
|
|
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.
Target Products:
|
|
|
|
Rejection Prophylaxis |
|
|
|
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.
Buyer Products:
Target Products:
|
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Penile |
|
|
|
Erectile Dysfunction (Impotence) |
|
|
|
Phosphodiesterase Type 5 Inhibitors (PDE-5 Inhibitors)
Therapeutics that inhibit the breakdown of phosphodiesters thereby increasing levels of Nitric Oxide which help in dilating the blood vessels in the penis.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that increase blood flow in the penis by dilating blood vessels.
Buyer Products:
|
|
|
|
Peyronie`s Disease |
|
|
|
Antifibrotic Agents
Therapeutics that treat fibrosis by increasing oxygen utilization at the tissue level, which in turn helps in the degradation of serotonin. A causal relationship is thought to exist between fibrosis and increased serotonin levels.
Buyer Products:
|
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Testicular |
|
|
|
Abnormal Puberty |
|
|
|
Delayed |
|
|
|
Androgens
Therapeutics that treat puberty disorders by providing male sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Buyer Products:
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Muscarinic Receptor Antagonists
Therapeutics that treat COPD by blocking the action of choline and other cholinergic agents from binding to the muscarinic receptor.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Anemia |
|
|
|
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.
Target Products:
|
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine without striping the body of potassium.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Renal Insufficiency |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that delay or treat kidney disease by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.
Target Products:
|
|
|
|
Prader-Willi Syndrome |
|
|
|
Growth Hormones
Therapeutics that treat a rare genetic disorder with a number of symptoms, the most significant of which is obesity, by supplying the body with growth hormones.
Buyer Products:
|
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Wound Management |
|
|
|
Bone Fractures |
|
|
|
Growth Factors |
|
|
|
Recombinant Human Bone Morphogenetic Proteins (rhBMP)
Therapeutics that promote healing of a broken bone by promoting the proliferation of bone cells.
Buyer Products:
|
|
|
|
Burns |
|
|
|
Complications |
|
|
|
Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Antifungal Agents |
|
|
|
Sulfonamides
Therapeutics that treat fungal infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Healthcare Services |
|
|
|
Patient Care |
|
|
|
Ambulatory/Outpatient |
|
|
|
Diagnostic |
|
|
|
Clinical Laboratories |
|
|
|
Pathology
Similar to routine clinical lab services, pathology services are provided by licensed medical physicians and therefore may involve the additional role of diagnosis and consultation of results with the referring physician.
Target Products:
|
|
|
|
Specialized
Specialized laboratory testing services involving highly specialized equipment, personnel, and procedures.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Cardiology |
|
|
|
Diagnostic |
|
|
|
Monitoring |
|
|
|
Monitors |
|
|
|
Stress/Exercise Test
Instruments used to evaluate the cardiopulmonary system during exercise.
Buyer Products:
|
|
|
|
Clinical Diagnostics |
|
|
|
Chemistry |
|
|
|
Analyzers |
|
|
|
Clinical Chemistry
Analyzers used to quantify various chemicals in blood plasma or serum samples. Blood gas and protein analyzers are included.
Target Products:
|
|
|
|
Urinalysis
Analyzers used to perform chemical, physical and microscopic analysis of urine.
Target Products:
|
|
|
|
Home Testing |
|
|
|
Glucose Testing/Diabetes Monitoring |
|
|
|
Invasive |
|
|
|
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis.
Target Products:
|
|
|
|
Random Analysis
Glucose test devices which measure patient glucose levels on a random basis.
Target Products:
|
|
|
|
Test Strips
Specific glucose test devices used with glucose monitors.
Target Products:
|
|
|
|
Urine |
|
|
|
Pregnancy
Home pregnancy testing kits.
Buyer Products:
|
|
|
|
Point of Care Testing |
|
|
|
Critical Care Analysis |
|
|
|
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.
Target Products:
|
|
|
|
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.
Target Products:
|
|
|
|
Kits |
|
|
|
Cardiac
Test kits used to aid in the diagnosis of heart conditions.
Target Products:
|
|
|
|
Reagents |
|
|
|
Calibrators
Specific standards of known concentration for analytes that are used to define test performance of chemistry analyzers, including blood gas analyzers and other routine analyte analyzers.
Target Products:
|
|
|
|
Controls
Materials with known concentrations used to verify the accuracy of test systems, including blood gas system, routine system, microbiology system, and other specialized systems.
Target Products:
|
|
|
|
Test Kits |
|
|
|
Genetic/Molecular Diagnostics |
|
|
|
Disease Diagnosis |
|
|
|
Infectious Diseases |
|
|
|
Automated Analyzers
Analyzers designed for genetic probe assays to detect and quantitate microorganisms.
Target Products:
|
|
|
|
Reagents |
|
|
|
Bacterial |
|
|
|
Tuberculosis
Genetic probe for detection and/or quantitation of Mycobacterium tuberculosis.
Target Products:
|
|
|
|
Viral |
|
|
|
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.
Target Products:
|
|
|
|
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.
Target Products:
|
|
|
|
Hepatitis C Virus
Genetic probes for detection and/or quantitation of HCV.
Target Products:
|
|
|
|
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.
Target Products:
|
|
|
|
Human Papilloma Virus
Genetic probes for the detection of HPV.
Target Products:
|
|
|
|
Influenza (Flu)
Genetic probes for detection and/or quantitation of Influenza (Flu) virus.
Target Products:
|
|
|
|
West Nile Virus
Genetic probes for detection and/or quantitation of West Nile Virus.
Target Products:
|
|
|
|
Oncology |
|
|
|
Colorectal Cancer/Colon Cancer
Tests designed to diagnose colorectal cancer/colon cancer through genetic detection and analysis.
Target Products:
|
|
|
|
Pharmacogenetic
Tests designed to determine patients' reactions to specific medications based on their genes.
Target Products:
|
|
|
|
Urinalysis
Test kits used to perform chemical and physical analysis of urine.
Target Products:
|
|
|
|
Hematology/Hemostasis |
|
|
|
Hematology |
|
|
|
Analyzers |
|
|
|
Multiple Parameter
Hematology analyzers designed for use in determining multiple hematological parameters in a clinical setting.
Target Products:
|
|
|
|
Hemostasis |
|
|
|
Analyzers |
|
|
|
Automated
Automated coagulation analyzers.
Target Products:
|
|
|
|
Reagents |
|
|
|
Test Kits |
|
|
|
Thrombin/Thromboplastin
Test kits used to perform thrombin time, prothrombin time, and activated partial thromboplastin time assays.
Target Products:
|
|
|
|
Histology |
|
|
|
Imaging Systems |
|
|
|
Cytopathology
Systems designed to enhance microscopic visualization of human cells through camera, video or digital viewing processes.
Target Products:
|
|
|
|
Processing Equipment |
|
|
|
Slide Processing
Slide processing equipment including slide labelers, slide makers, and immunohistochemistry and in-situi hybridization slide stainers.
Target Products:
|
|
|
|
Tissue Processing
Instrument used for the automated processing and embedding of tissue samples.
Target Products:
|
|
|
|
Reagents |
|
|
|
Biomolecular Stains
Vital reagents used in the staining of tissue in order to view microscopically for pathology.
Target Products:
|
|
|
|
Kits |
|
|
|
DNA Probes
Staining kits which utilize DNA probes to mark specific cells for staining.
Target Products:
|
|
|
|
In-Situ Hybridization (ISH)
Staining kits which utilize In-Situ hybridization techniques to mark specific cells for staining.
Target Products:
|
|
|
|
Preparation/Preservation
Reagents used for preservation of tissues and preparation of tissues for analysis.
Target Products:
|
|
|
|
Immunoassays |
|
|
|
Analyzers |
|
|
|
Accessories
Reagents and equipment used to facilitate immunoassay testing.
Target Products:
|
|
|
|
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.
Target Products:
|
|
|
|
Reagents |
|
|
|
Calibrators
Specific standards of known concentration for analytes that are used to define and or measure test performance of immunoassay test kits and systems.
Target Products:
|
|
|
|
Controls
Reagents used to verify the function and reliability of immunoassay test kits and systems.
Target Products:
|
|
|
|
Test Kits |
|
|
|
Allergy
Immunassay kits used to detect and quantitate allergy associated analytes.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Cardiac
Immunoassay kits used to screen, diagnose or monitor cardiac conditions.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial
Immunoassay kits which test for the presence of infectious diseases or previous infection caused by bacteria.
Buyer Products:
Target Products:
|
|
|
|
Viral
Immunoassay kits which test for the presence of infectious disease or previous infection caused by viruses.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer
Diagnostic assay used to detect specific breast tumor or cancer markers.
Target Products:
|
|
|
|
Cervical Cancer
Diagnostic assay used to detect specific cervical tumor or cancer markers.
Target Products:
|
|
|
|
Digestive System Cancer
Diagnostic assay used to detect specific digestive system cancer markers.
Target Products:
|
|
|
|
Multiple Tumor
Diagnostic assay used to detect markers associated with multiple cancer types.
Target Products:
|
|
|
|
Opthalmology
Immunoassay kits used to quantify markers associated with opthalmic diseases.
Target Products:
|
|
|
|
Toxicology/Drugs Of Abuse |
|
|
|
Drugs Of Abuse
Immunoassay test kits which test for drugs of abuse in body fluids.
Target Products:
|
|
|
|
Therapeutic Drugs
Immunoassay test kits which measure levels of therapeutic drugs in body fluids.
Target Products:
|
|
|
|
Specimen Collection |
|
|
|
Blood |
|
|
|
Capillary |
|
|
|
Lancets
Sharps type of device used to puncture the skin in order to collect a capillary blood sample.
Target Products:
|
|
|
|
Drug Delivery |
|
|
|
Infusion Therapy |
|
|
|
Delivery Systems |
|
|
|
Insulin |
|
|
|
Pumps |
|
|
|
External/Random Analysis Monitoring System
External pump that delivers insulin to the patient and measure patient glucose levels as a blood sample is obtained.
Target Products:
|
|
|
|
Implanted
Implanted pump that delivers insulin to the patient.
Target Products:
|
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
|
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.
Buyer Products:
|
|
|
|
General Surgery |
|
|
|
Invasive |
|
|
|
Surgical-Site Treatments |
|
|
|
Sealants |
|
|
|
Hemostatic |
|
|
|
Topical
Topical mixture used when conventional hemostasis procedures are not effective.
Buyer Products:
|
|
|
|
Orthopedics |
|
|
|
Surgical |
|
|
|
Procedure Specific |
|
|
|
Bone Loss Reconstruction |
|
|
|
Maxillofacial
Devices used to reconstruct areas of bone loss in maxillofacial region.
Buyer Products:
|
|
|
|
Tibia
Devices used to reconstruct areas of bone loss in the tibia/lower leg.
Buyer Products:
|
|
|
|
Joint Replacement/Reconstruction |
|
|
|
Spine |
|
|
|
Spinal Implants |
|
|
|
Bone Growth Stimulators
Implantable devices that stimulate bone growth
Buyer Products:
|
|
|
|
Radiology |
|
|
|
Nuclear |
|
|
|
Gamma Camera |
|
|
|
Contrast Agents |
|
|
|
Radionuclides |
|
|
|
Adjuncts
Radioactive materials that are introduced to the body for nuclear imaging purposes.
Buyer Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Buyer Products:
|
|
|
|
Men`s Health
Products consisting of dietary/naturopathic supplements that are intended to support men's health.
Buyer Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Buyer Products:
|
|
|
|
Outsourced Biomedical Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Bioanalytical Services |
|
|
|
Nucleic Acid Sequencing
Bioanalytical services that identify the location of each nucleotide in a nucleic acid sample.
Target Products:
|
|
|
|
Nucleic Acid Synthesis
Bioanalytical services that produce nucleic acids from individual nucleotides.
Target Products:
|
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Biopharmaceutical OEM |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.
Buyer Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Assay Development
Bioanalytical services that are used to develop biologically based tests for use in high throughput screening (HTS).
Target Products:
|
|
|
|
High Throughput Screening (HTS)
Bioanalytical services that allow for the biological testing of up to 10,000 compounds each day.
Target Products:
|
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Target Products:
|
|
|
|
Target Discovery/Validation |
|
|
|
Databases |
|
|
|
Genomics |
|
|
|
Human
Genomic databases that contain human genetic information.
Target Products:
|
|
|
|
Services
Drug discovery services that discover and validate drug targets for the development of novel biopharmaceutical drugs.
Target Products:
|
|
|
|
Scientific Products |
|
|
|
Analytical Instruments |
|
|
|
Automation/Processing Equipment |
|
|
|
Automation Equipment |
|
|
|
Robotic Instruments |
|
|
|
Workstations
Robotic instrument systems that transfer liquid and gas samples and also heat and cool samples.
Target Products:
|
|
|
|
Bioanalytical Instruments |
|
|
|
Bioanalytical Consumables |
|
|
|
Cell Biology |
|
|
|
Cell Culture |
|
|
|
Cell Lines
Cell biology consumables that is a permanently established cell culture which proliferates indefinitely given appropriate fresh medium and space.
Target Products:
|
|
|
|
Hybridomas
Cell culture reagents that are used to support Hybridomas for antibody production.
Target Products:
|
|
|
|
Media
Cell biology consumables used for the growth of cells or organs.
Target Products:
|
|
|
|
Reagents |
|
|
|
Lymphokines/Cytokines
Cell culture reagents that are used during cellular assays.
Target Products:
|
|
|
|
Stains/Dyes
Cell culture reagents used for the coloration of samples.
Target Products:
|
|
|
|
Immunology |
|
|
|
Kits |
|
|
|
Enzyme-Linked Immunoabsorbent Assay (ELISA)
Kits used for the generalized analysis of serum samples for the detection of antibodies to infectious diseases.
Target Products:
|
|
|
|
Reagents |
|
|
|
Proteins |
|
|
|
Antibodies
Immunology proteins that are used for the detection of specific substances, including conjugated, unconjugated, monoclonal and polyclonal antibodies.
Target Products:
|
|
|
|
Cytokines
Immunology reagents that are used as intracellular mediators.
Target Products:
|
|
|
|
Enzymes
Immunology reagents that are produced by a living organism to catalyze a chemical reaction.
Target Products:
|
|
|
|
Molecular Biology |
|
|
|
Electrochemiluminescence (ECL) |
|
|
|
Reagents
Chemicals used in the preparation and analysis of samples.
Target Products:
|
|
|
|
Nucleic Acid Analysis |
|
|
|
Automated Nucleic Acid Purification Systems
Fully automated systems for purification of DNA/RNA from blood samples.
Target Products:
|
|
|
|
Kits |
|
|
|
Nucleic Acid |
|
|
|
Sequencing
Nucleic acid analysis kits that are used for the sequencing of genetic samples.
Target Products:
|
|
|
|
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA
Target Products:
|
|
|
|
Polymerase Chain Reaction (PCR) |
|
|
|
Amplification
Polymerase chain reaction (PCR) consumables used for the amplification of genetic samples.
Target Products:
|
|
|
|
Detection
Polymerase chain reaction (PCR) consumables used for the detection of genetic samples.
Target Products:
|
|
|
|
Purification
Polymerase chain reaction (PCR) consumables used for the purification of genetic samples.
Target Products:
|
|
|
|
Reagents |
|
|
|
Nucleic Acids
Nucleic acid analysis reagents that are made of nucleotides.
Target Products:
|
|
|
|
Protein Analysis |
|
|
|
Kits |
|
|
|
Detection
Protein analysis kits used for the detection of amino acids.
Target Products:
|
|
|
|
Expression
Kits used to perform protein expression analysis.
Target Products:
|
|
|
|
Biomolecular |
|
|
|
Microarray Technology |
|
|
|
Consumables
Molecular biology consumables used for microarray and biochip instrumentation. Includes kits, chips, and reagents.
Target Products:
|
|
|
|
Microplate Readers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a microplate reader, including detectors, incubators, dispensers, plate handlers, validation plates, and washers. Also includes consumable microplate reader kits.
Target Products:
|
|
|
|
Systems |
|
|
|
Multiple Parameter
Microplate reader systems that used a combination of fluorescent, luminescent, and/or photoemission detectors.
Target Products:
|
|
|
|
Single Parameter |
|
|
|
Electrochemiluminescence (ECL)
Microplate reader systems that use electrochemiluminescent (ECL) detectors.
Target Products:
|
|
|
|
Sequencers |
|
|
|
Automated |
|
|
|
Nucleic Acid
Automated sequencers that employ gel electrophoresis or capillary electrophoresis to analyze nucleic acid samples.
Target Products:
|
|
|
|
Synthesizers |
|
|
|
Deoxyribonucleic Acid (DNA)/Oligonucleotides
Synthesizer system used for the identification and synthesis of nucleic acid samples.
Target Products:
|
|
|
|
Peptides
Synthesizer systems used for the identification and synthesis of peptide samples.
Target Products:
|
|
|
|
Thermal Cyclers |
|
|
|
Accessories
Supplementary products used to enhance the performance of a thermal cycler.
Target Products:
|
|
|
|
Systems
Thermal cycler components assembled as a single unit.
Target Products:
|
|
|
|
Cellular |
|
|
|
Flow Cytometers |
|
|
|
Systems
Flow cytometer components assembled as a single unit.
Target Products:
|
|
|
|
Veterinary Products and Services |
|
|
|
Veterinary Diagnostics
The Veterinary Diagnostics Subsector includes companies that manufacture veterinary diagnostics for the detection and monitoring of veterinary diseases.
Buyer Products:
|
|
|
|
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.
Buyer Products:
|
|
|
|
Technology |
|
|
|
Information Technology (IT) Services |
|
|
|
Enterprise and Technology Consulting |
|
|
|
Industry-Specific IT Services |
|
|
|
Healthcare
IT solutions tailored and marketed for the healthcare industry.
Target Products:
|
|
|
|
Software |
|
|
|
Industry-Specific |
|
|
|
Healthcare/Pharma |
|
|
|
Business Management/Information Systems |
|
|
|
Patient Data Management |
|
|
|
Medical Image/PACS Management
Data management/PACS (Picture Archiving and Communication System) systems that are designed to store, index, access, and distribute digital medical images, such as x-rays.
Target Products:
|
|
|
|
Drug Development |
|
|
|
Molecular Biology |
|
|
|
General Imaging
Software that is used to capture, analyze, store, or enhance molecular biology images that are not specific to any given imaging process.
Target Products:
|
|
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Johnson & Johnson
|
|
n/a | 173,601.426 | 9.96 | 12.41 | 1.53 | 2.61 | n/a | |
|
Merck & Co Inc
|
|
n/a | 116,518.823 | 16.80 | 9.96 | 2.42 | 2.49 | 12.01 | |
|
GlaxoSmithKline PLC
|
|
n/a | 112,212.429 | 14.92 | 11.28 | 3.53 | 2.50 | n/a | |
|
Abbott Laboratories
|
|
n/a | 95,838.446 | 18.66 | 12.30 | 2.44 | 2.42 | n/a | |
|
Sanofi
|
|
n/a | 92,247.629 | 18.09 | 8.74 | 2.16 | 2.01 | n/a | |
|
Amgen Inc
|
|
n/a | 63,900.920 | 17.21 | 11.66 | 4.01 | 3.99 | 19.32 | |
|
Astrazeneca PLC
|
|
n/a | 55,862.085 | 6.70 | 6.82 | 1.71 | 1.94 | 90.39 | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Eli Lilly & Co
|
|
n/a | 46,816.943 | 10.86 | 12.39 | 1.95 | 2.07 | 4.89 | |
|
Gilead Sciences Inc
|
|
n/a | 38,526.468 | 14.94 | 14.61 | 4.41 | 4.22 | n/a | |
|
Biogen IDEC Inc
|
|
n/a | 31,914.176 | 25.95 | 21.64 | 6.21 | 6.01 | 9.58 | |
|
Celgene Corp
|
|
n/a | 31,244.689 | 21.68 | 15.88 | 6.26 | 5.82 | 5.14 | |
|
Allergan Inc
|
|
n/a | 27,300.906 | 27.16 | 21.26 | 4.93 | 4.66 | 12.31 | |
|
Vertex Pharmaceuticals Inc
|
|
n/a | 12,764.112 | n/a | 24.31 | 6.90 | 6.68 | 54.08 | |
|
Regeneron Pharmaceuticals Inc
|
|
n/a | 11,016.269 | n/a | 117.51 | 19.48 | 10.86 | 21.86 | |
|
Warner Chilcott PLC
|
|
n/a | 5,056.104 | 16.51 | 5.90 | 1.90 | 2.08 | n/a | |
|
Amylin Pharmaceuticals Inc
|
|
n/a | 3,909.943 | n/a | -14.63 | 6.01 | 5.87 | n/a | |
|
Onyx Pharmaceuticals Inc
|
|
n/a | 2,657.434 | n/a | -13.95 | 5.88 | 9.14 | 17.82 | |
|
Seattle Genetics Inc
|
|
n/a | 2,301.496 | n/a | -42.29 | 17.59 | 10.75 | 10.45 | |
|
Ariad Pharmaceuticals Inc
|
|
n/a | 2,118.104 | n/a | -12.64 | 83.65 | 186.35 | 8.23 | |
|
Vivus Inc
|
|
n/a | 1,990.468 | n/a | -36.94 | n/a | 27.69 | 6.11 | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 173,601.426 | 9.96 | 12.41 | 1.53 | 2.61 | n/a | |
|
Roche Holding AG
|
|
n/a | 139,114.120 | 24.15 | 10.09 | 2.04 | 2.93 | n/a | |
| Target | |||||||||
|
Pfizer Inc
|
|
n/a | 176,093.984 | 12.76 | 10.21 | 1.76 | 2.93 | n/a | |
|
Johnson & Johnson
|
|
n/a | 173,601.426 | 9.96 | 12.41 | 1.53 | 2.61 | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
PDI Inc
|
|
42.70% | 128.386 | n/a | 78.09 | 0.90 | 0.83 | 2.16 | |
|
Marina Biotech Inc
|
|
2.00% | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Alexandria Real Estate Equities Inc
|
|
1.30% | 4,573.396 | 35.80 | 16.27 | 5.31 | 7.80 | 1.35 | |
|
Biomed Realty Trust Inc
|
|
n/a | 2,412.092 | 85.25 | 14.58 | 4.31 | 5.03 | 0.94 | |
|
Seattle Genetics Inc
|
|
n/a | 2,301.496 | n/a | -42.29 | 17.59 | 10.75 | 10.45 | |
|
PDL Biopharma Inc
|
|
n/a | 863.931 | 5.47 | 4.32 | 1.34 | 2.29 | n/a | |
|
Nektar Therapeutics
|
|
n/a | 733.425 | n/a | -5.19 | 9.39 | 9.32 | 8.53 | |
|
Medidata Solutions Inc
|
|
n/a | 666.218 | 16.54 | 31.29 | 3.43 | 3.13 | 6.99 | |
|
Sangamo Biosciences Inc
|
|
n/a | 228.217 | n/a | -8.49 | 20.09 | 13.91 | 3.07 | |
|
Dyax Corp
|
|
n/a | 158.984 | n/a | -5.03 | 3.06 | 3.06 | n/a | |
|
EnerNoc Inc
|
|
n/a | 149.075 | n/a | -4.07 | 0.53 | 0.58 | 1.31 | |
|
Compugen Ltd
|
|
n/a | 123.460 | n/a | n/a | n/a | n/a | 6.31 | |
|
Codexis Inc
|
|
n/a | 112.024 | n/a | -5.42 | 0.90 | 0.89 | 1.45 | |
|
Tekmira Pharmaceuticals Corporation
|
|
n/a | 24.268 | n/a | -3.67 | 1.45 | 1.42 | 4.57 | |
|
Morphosys AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Gerresheimer AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Ypsomed Holding AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Andreae-Noris Zahn AG ANZAG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Protalix BioTherapeutics Inc
|
|
100.00% | 530.623 | n/a | 86.86 | 764.82 | 17.46 | n/a | |
|
pSivida Corp
|
|
67.00% | 41.485 | n/a | -1.66 | 6.52 | 11.65 | 3.14 | |
| Target | |||||||||
|
Synageva BioPharma Corp
|
|
96.00% | n/a | n/a | -19.72 | n/a | n/a | n/a | |
|
PDL Biopharma Inc
|
|
86.00% | 863.931 | 5.47 | 4.32 | 1.34 | 2.29 | n/a | |
|
Seattle Genetics Inc
|
|
77.00% | 2,301.496 | n/a | -42.29 | 17.59 | 10.75 | 10.45 | |
|
Alnylam Pharmaceuticals Inc
|
|
56.00% | 422.679 | n/a | -7.75 | 5.13 | 6.77 | 2.14 | |
|
PDI Inc
|
|
13.80% | 128.386 | n/a | 78.09 | 0.90 | 0.83 | 2.16 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 225.606 | 0.46 | n/a | 0.01 | n/a | 0.03 | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Corporativo Fragua SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
McKesson Corp
|
|
13.00% | 21,539.311 | 37.45 | 12.17 | 0.18 | 0.17 | n/a | |
|
Cardinal Health Inc
|
|
10.00% | 14,360.023 | 13.91 | 12.97 | 0.13 | 0.14 | 7.68 | |
| Target | |||||||||
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
|
Regeneron Pharmaceuticals Inc
|
|
n/a | 11,016.269 | n/a | 117.51 | 19.48 | 10.86 | 21.86 | |
|
Gen-Probe Inc
|
|
n/a | 3,886.346 | 54.62 | 30.87 | 5.33 | 6.07 | 9.47 | |
|
Ironwood Pharmaceuticals Inc
|
|
n/a | 1,130.628 | n/a | -9.35 | 16.66 | 11.56 | 6.89 | |
|
Genomic Health Inc
|
|
n/a | 933.427 | 114.21 | n/a | 4.35 | 4.06 | 7.62 | |
|
PDL Biopharma Inc
|
|
n/a | 863.931 | 5.47 | 4.32 | 1.34 | 2.29 | n/a | |
|
Abaxis Inc
|
|
n/a | 748.169 | 74.30 | 39.49 | 4.78 | 4.32 | 4.80 | |
|
Nektar Therapeutics
|
|
n/a | 733.425 | n/a | -5.19 | 9.39 | 9.32 | 8.53 | |
|
Orasure Technologies Inc
|
|
n/a | 488.971 | n/a | -47.41 | 5.72 | 5.06 | 10.87 | |
|
Curis Inc
|
|
n/a | 342.159 | n/a | -35.92 | 13.69 | 16.24 | 8.86 | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 225.606 | 0.46 | n/a | 0.01 | n/a | 0.03 | |
|
Heska Corporation
|
|
n/a | 65.072 | 30.21 | 18.53 | 0.93 | 0.78 | 1.34 | |
|
Peregrine Pharmaceuticals Inc
|
|
n/a | 31.271 | n/a | -0.93 | 1.97 | 1.82 | 2.42 | |
|
Response Genetics Inc
|
|
n/a | 29.306 | n/a | -3.48 | 1.42 | 1.55 | n/a | |
|
Helicos BioSciences Corp
|
|
n/a | 7.859 | n/a | n/a | 3.03 | n/a | n/a | |
|
Fleury SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PT Tempo Scan Pacific Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
PT Enseval Putera Megatrading Tbk
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Corporativo Fragua SAB de CV
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Rel. Revenue % | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
GlaxoSmithKline PLC
|
|
n/a | 112,212.429 | 14.92 | 11.28 | 3.53 | 2.50 | n/a | |
|
Abbott Laboratories
|
|
n/a | 95,838.446 | 18.66 | 12.30 | 2.44 | 2.42 | n/a | |
|
Amgen Inc
|
|
n/a | 63,900.920 | 17.21 | 11.66 | 4.01 | 3.99 | 19.32 | |
|
Astrazeneca PLC
|
|
n/a | 55,862.085 | 6.70 | 6.82 | 1.71 | 1.94 | 90.39 | |
|
Bristol Myers Squibb Co
|
|
n/a | 55,809.424 | 14.67 | 16.79 | 2.60 | 3.12 | 11.82 | |
|
Eli Lilly & Co
|
|
n/a | 46,816.943 | 10.86 | 12.39 | 1.95 | 2.07 | 4.89 | |
|
Gilead Sciences Inc
|
|
n/a | 38,526.468 | 14.94 | 14.61 | 4.41 | 4.22 | n/a | |
|
Mylan Inc
|
|
n/a | 8,870.955 | 15.88 | 8.53 | 1.41 | 1.31 | n/a | |
|
Seattle Genetics Inc
|
|
n/a | 2,301.496 | n/a | -42.29 | 17.59 | 10.75 | 10.45 | |
|
Genomic Health Inc
|
|
n/a | 933.427 | 114.21 | n/a | 4.35 | 4.06 | 7.62 | |
|
PDL Biopharma Inc
|
|
n/a | 863.931 | 5.47 | 4.32 | 1.34 | 2.29 | n/a | |
|
Nektar Therapeutics
|
|
n/a | 733.425 | n/a | -5.19 | 9.39 | 9.32 | 8.53 | |
|
Exelixis Inc
|
|
n/a | 594.572 | 7.41 | -4.38 | 2.18 | 11.33 | 8.66 | |
|
Clovis Oncology Inc
|
|
n/a | 460.194 | n/a | -6.31 | n/a | 2.97 | 4.04 | |
|
Sangamo Biosciences Inc
|
|
n/a | 228.217 | n/a | -8.49 | 20.09 | 13.91 | 3.07 | |
|
Grupo Casa Saba, S.A. (ADR)
|
|
n/a | 225.606 | 0.46 | n/a | 0.01 | n/a | 0.03 | |
|
Compugen Ltd
|
|
n/a | 123.460 | n/a | n/a | n/a | n/a | 6.31 | |
|
Faes Farma SA
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
EIS Eczacibasi Ilac Sanayi ve Ticaret A.S.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Yiaco Medical Co. K.S.C.C
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Buyer | |||||||||
|
Johnson & Johnson
|
|
n/a | 173,601.426 | 9.96 | 12.41 | 1.53 | 2.61 | n/a | |
|
GlaxoSmithKline PLC
|
|
n/a | 112,212.429 | 14.92 | 11.28 | 3.53 | 2.50 | n/a | |
| Target | |||||||||
|
International Business Machines Corp IBM
|
|
n/a | 233,935.175 | 14.85 | 13.18 | 2.19 | 2.19 | n/a | |
|
Novartis SA
|
|
n/a | 142,003.622 | 16.43 | 9.70 | 2.40 | 2.46 | 101.58 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 99,814.0 | 68,347.2 | 168,161.2 |
|
Other Revenue
|
n/a | n/a | n/a |
| Total Revenue | 99,814.0 | 68,347.2 | 168,161.2 |
|
Cost of Revenue
|
21,785.0 | 13,313.8 | 35,098.8 |
|
SG&A Expense
|
28,446.0 | 10,836.3 | 39,282.3 |
|
Depreciation & Amortization
|
8,400.0 | 11.0 | 8,411.0 |
|
Research & Development
|
12,530.0 | 8,955.3 | 21,485.3 |
|
Interest Expense
|
287.0 | n/a | 287.0 |
|
Other Operating Expense
|
259.0 | -1,761.1 | -1,502.1 |
|
Unusual Expense (Income)
|
7,848.0 | 943.1 | 8,791.1 |
| Total Expenses | 80,817.0 | 32,298.5 | 113,115.5 |
|
Operating Income
|
18,997.0 | 36,048.7 | 55,045.7 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
n/a | -1,249.5 | -1,249.5 |
|
Other, Net
|
n/a | 449.8 | 449.8 |
| Income Before Taxes | 18,997.0 | 13,385.1 | 32,382.1 |
| Income Taxes | 5,867.0 | 2,658.0 | 8,525.0 |
| Income After Taxes | 13,130.0 | 10,727.1 | 23,857.1 |
| Minority Interest (IS) | -59.0 | -225.3 | -284.3 |
|
Net Income - Excl. Xord. Items
|
13,071.0 | 10,501.8 | 23,572.8 |
| Discontinued Operations | 1,342.0 | n/a | 1,342.0 |
|
Net Income - Incl. Xord. Items
|
14,413.0 | 10,501.8 | 24,914.8 |
|
Income Avail. to Common
|
14,413.0 | 10,501.8 | 24,914.8 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
7,537.0 | 848.0 | 8,385.0 |
|
Basic EPS - Excl. Xord. Items
|
1.66 | 12.37 | 2.81 |
|
Basic EPS - Incl. Xord. Items
|
1.83 | 6.80 | 2.97 |
| Full Dilution Adjustment | n/a | -1.0 | -1.0 |
| Fully Diluted Shares Outstanding | 7,598.0 | 849.2 | 8,447.2 |
|
F.D. EPS - Excl. Xord. Items
|
1.65 | 6.78 | 2.79 |
|
F.D. EPS - Incl. Xord. Items
|
1.82 | 6.78 | 2.95 |
| Dividends Per Common Share | 1.22 | 6.80 | 8.02 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
2,934.0 | 3,854.0 | 6,788.0 |
|
ST Investments
|
21,038.0 | 7,433.0 | 28,471.0 |
|
Accounts Receivable
|
14,182.0 | 9,799.0 | 23,981.0 |
|
Inventory
|
7,189.0 | 5,060.0 | 12,249.0 |
|
Other Current Assets
|
9,520.0 | 2,086.0 | 11,606.0 |
|
Current Assets
|
54,863.0 | 28,232.0 | 83,095.0 |
|
Accum D&A
|
n/a | n/a | n/a |
|
PPE, Net
|
16,192.0 | 16,201.0 | 32,393.0 |
| Goodwill & Intangibles | 98,053.0 | 12,969.0 | 111,022.0 |
| Long Term Investments | 10,632.0 | 384.0 | 11,016.0 |
| Other Assets | n/a | n/a | n/a |
|
Other LT Assets
|
5,943.0 | 3,790.0 | 9,733.0 |
| Total Assets | 185,683.0 | 61,576.0 | 247,259.0 |
| Liabilities | |||
| Accounts Payable | 3,091.0 | 2,053.0 | 5,144.0 |
| Payable/Accrued | n/a | n/a | n/a |
| Accrued Expenses | 1,752.0 | 7,511.5 | 9,263.5 |
|
ST Debt
|
5,526.0 | n/a | 5,526.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
n/a | 3,394.0 | 3,394.0 |
| Other (Current) Liabilities | 16,725.0 | 10,763.0 | 27,488.0 |
|
Current Liab.
|
27,094.0 | 16,210.0 | 43,304.0 |
|
LT Debt
|
33,543.0 | 23,459.0 | 57,002.0 |
|
Total LT Debt
|
33,543.0 | 23,459.0 | 57,002.0 |
| Minority Interest (BS) | 421.0 | 2,387.0 | 2,808.0 |
| Deferred Taxes | 19,739.0 | 604.0 | 20,343.0 |
|
Other LT Liab.
|
21,630.0 | 6,821.0 | 28,451.0 |
|
Total Liabilities
|
102,427.0 | 49,481.0 | 151,908.0 |
| Shareholders Equity | |||
| Preferred Stock | 43.0 | n/a | 43.0 |
| Common Stock | 446.0 | 160.0 | 606.0 |
| Additional Paid in Capital | 71,786.0 | n/a | 71,786.0 |
| Retained Earnings | 48,124.0 | 17,369.0 | 65,493.0 |
| Treasure Stock | -33,519.0 | n/a | -33,519.0 |
| Other Equity | -3,622.0 | -5,434.0 | -9,056.0 |
| ESOP Debt Guarantee | -2.0 | n/a | -2.0 |
|
Total Equity
|
83,256.0 | 12,095.0 | 95,351.0 |
|
Total Liab. & Equity
|
185,683.0 | 61,576.0 | 247,259.0 |
|
Shares Outstanding
|
7,488.1 | 862.6 | 8,350.7 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 9,620.0 | 9,544.0 | 19,164.0 |
| CF Depreciation | 9,174.0 | 1,848.0 | 11,022.0 |
| CF Amortization | n/a | 520.0 | 520.0 |
| CF Deferred Taxes | -20.0 | n/a | -20.0 |
| Other Non-Cash Items | 412.0 | 4,120.8 | 4,532.8 |
| Change in Working Capital | -814.0 | 4,910.4 | 4,096.4 |
| Total Cash From Operating Activities | 18,372.0 | 20,943.2 | 39,315.2 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -1,664.0 | -3,450.8 | -5,114.8 |
| Other Investing Cash Flows | 3,590.0 | 5,803.7 | 9,393.7 |
| Total Cash From Investing Activities | 1,926.0 | 2,352.9 | 4,278.9 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -6,293.0 | -12,710.8 | -19,003.8 |
| Purchase Or Sale of Stock | -9,059.0 | n/a | -9,059.0 |
| Purchase and Retirement of Debt | -2,358.0 | -2,136.1 | -4,494.1 |
| Other Financing Cash Flow | n/a | -2,310.6 | -2,310.6 |
| Total Cash From Financing Activities | -17,710.0 | -20,903.5 | -38,613.5 |
| Exchange Rate Effects | -27.0 | -123.7 | -150.7 |
| Net Change in Cash | 2,561.0 | 2,269.0 | 4,830.0 |
| Cash Taxes Paid | 3,523.0 | 3,924.3 | 7,447.3 |
| Cash Interest Paid | 1,906.0 | 3,084.9 | 4,990.9 |